REG - BiVictriX Therapcts. - Result of General Meeting

Bivictrix TherapeuticsAnnouncement

08/08/2023 17:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230808:nRSH7024Ia&default-theme=true

RNS Number : 7024I  BiVictriX Therapeutics PLC  08 August 2023

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO
CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER ARTICLE 7 OF THE EU
REGULATION 596/2014 AS IT FORMS PART OF THE UK LAW BY VIRTUE OF THE EUROPEAN
UNION (WITHDRAWAL) ACT 2018 ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT
VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN
THE PUBLIC DOMAIN.

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company")

 

Result of General Meeting

Completion of Fundraise

Total Voting Rights

Alderley Park, 8 August 2023 - BiVictriX Therapeutics plc (AIM: BVX), an
emerging biotechnology company applying a differentiated approach to develop
next-generation cancer therapies with substantially improved cancer cell
selectivity and anti-cancer activity, announces that at the Company's General
Meeting held today at 11:00 a.m. at the Company's registered office, Mereside
Alderly Park, Alderly Edge, Manchester SK10 4TG, all resolutions were duly
passed. Further details of each of the resolutions are set out in the Circular
and Notice of Meeting, which was sent to shareholders on 20 July 2023 (the
"Circular").

 

Details of proxy votes received are summarised below:

 

 Resolution                                                                       Votes For   Votes Against  Discretionary Votes  Withheld
 Ordinary Resolution
 In accordance with section 551 of the Companies Act 2006, the directors of the   20,010,176  1              -                    -
 Company in addition to all previous authorities granted to the Directors, be
 generally and unconditionally authorised to exercise all the powers of the
 Company to allot shares in the Company, and grant rights to subscribe for or
 convert any securities into shares in the Company, up to an aggregate nominal
 amount of £164,108.87 (within the meaning of sections 551(3) and (6) of the
 said Act), in connection with the Fundraise detailed in the Circular.
 Special Resolution
 In accordance with section 570 of the Act, the Directors be generally            20,010,176  1              -                    -
 empowered to allot equity securities (as defined in section 560(1) of the Act)
 which are the subject of the authority conferred by resolution 1 as if section
 561 of the Act did not apply to such allotment, provided that this power shall
 be limited to the allotment of equity securities up to an aggregate nominal
 amount of £164,108.87, in connection with the Fundraise detailed in the
 Circular.

 

Completion of Fundraise

The Resolutions were necessary to implement the Fundraise to raise a total of
£2.1 million (before expenses), as announced by the Company on 19 July 2023.

 

Following the passing of the Resolutions, the Company has allotted (subject
only to Admission) the Placing Shares and the Subscription Shares with new and
existing investors (the "New Ordinary Shares"). The New Ordinary Shares will
rank pari passu with the Company's Existing Ordinary Shares.

 

Admission to AIM and Total Voting Rights

Application has been made for the Admission of 16,410,887 New Ordinary Shares.
It is expected that Admission will take place and that trading in the New
Ordinary Shares will commence, at 8.00 a.m. on 10 August 2023.

 

Following Admission, the Company's issued and fully paid share capital will
consist of 82,526,088 Ordinary Shares. The Company has no Ordinary Shares in
treasury. As such, the total number of voting rights in the Company will be
82,526,088 Ordinary Shares. Following Admission, this number may be used by
shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest, or a change to their
interest in, the Company under the FCA's Disclosure Guidance and Transparency
Rules.

 

Note

This announcement should be read in conjunction with the full text of the
Circular sent to shareholders on 20 July 2023 in connection with the
Fundraise. Capitalised terms used but not otherwise defined in this
announcement bear the meanings ascribed to them in the Circular.

 

 For more information, please contact:

BiVictriX Therapeutics plc
 Tiffany Thorn, Chief Executive Officer

 Michael Kauffman, Non-Executive Chairman             Email: info@bivictrix.com (mailto:info@bivictrix.com)

 SP Angel Corporate Finance LLP (NOMAD and Broker)    Tel: +44 (0) 20 3470 0470
 David Hignell, Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre, Rob Rees (Sales and Broking)

 Panmure Gordon (UK) Limited (Joint Broker)           Tel: +44 (0) 20 7886 2500
 Rupert Dearden/Freddy Crossley/Emma Earl

 Consilium Strategic Communications
 Mary-Jane Elliott, Namrata Taak,                     Tel: +44 (0) 20 3709 5700

 Max Bennett, Emmalee Hoppe                           Email: Bivictrix@consilium-comms.com (mailto:Bivictrix@consilium-comms.com)

 

About BiVictriX Therapeutics plc

 

BiVictriX (AIM: BVX) is an emerging biotechnology company leveraging clinical
experience and its proprietary discovery engine to advance a new class of
highly cancer-selective, next-generation precision cancer therapies in one of
the fastest-growing markets in oncology. BiVictriX's first-in-class Bi-Cygni®
Antibody Drug Conjugates (ADCs) combine superior efficacy with substantially
improved cancer-selectivity and safety to provide opportunities for prolonged
dosing and greater efficacy in the clinic. The Company is advancing its
pipeline to deliver the future of cancer care across a broad range of
haematological and solid cancer indications in areas of high unmet medical
need.

 

Find out more at www.bivictrix.com (http://www.bivictrix.com/)  and connect
with us on LinkedIn
(https://www.linkedin.com/company/bivictrix-therapeutics-plc/)  and
Twitter @BiVictriX (https://twitter.com/BiVictriX) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMQVLFBXVLFBBE